GENFIT GENFIT HONORED AT THE 'INVESTOR AWARDS 2014' ORGANIZED BY BOURSORAMA AND MORNINGSTAR
Lille (France), Boston (Massachusetts, United States), November 28, 2014 - GENFIT (Euronext: GNFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces that it has been honored at the INVESTOR AWARDS 2014 in the "Young Talent" category.
GENFIT was considered the overall favorite company listed on the stock exchange for less than 10 years, outside of the CAC 40. This prize results from a vote that took place between August 28th and November 2nd, 2014, amongst members of the Boursorama and Morningstar web-sites, both professionals and individuals, as well as all French accredited asset management companies.
Jean-François Mouney, Chairman and Chief Executive Officer of GENFIT, declared: "This distinction rewards our efforts in terms of communication of information with all our shareholders. Whether they are individual shareholders or representatives of the most prestigious financial institutions, we are committed to keeping them informed. This communication policy is our way of sharing with them our enthusiasm in the discovery and development of innovative medicines for insufficiently met medical needs."
About GENFIT:
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide.
GENFIT's R&D efforts are focused on contributing to bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). GENFIT implements mutually beneficial approaches that combine novel treatments and biomarkers; its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including GENFIT's lead proprietary compound, GFT505, that is completing a Phase 2b study in NASH. With facilities in Lille, France, and Boston, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT; ISIN: FR0004163111). www.genfit.com:
http://www.genfit.com
Disclaimer:
This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Euronext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on GENFIT's website (www.genfit.com).
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country.
Contacts GENFIT | Jean-François Mouney - CEO & Chairman of the Management Board | Ph. +333 2016 4000
MILESTONES - Relation Presse | Bruno Arabian | Ph. +331 8362 3484 / +336 8788 4726 - barabian@milestones.fr |
http://hugin.info/143426/R/1874945/660629.pdf
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: GENFIT via Globenewswire
